Page last updated: 2024-09-05

sorafenib and floxuridine

sorafenib has been researched along with floxuridine in 3 studies

Compound Research Comparison

Studies (sorafenib)	Trials (sorafenib)	Recent Studies (post-2010) (sorafenib)	Studies (floxuridine)	Trials (floxuridine)	Recent Studies (post-2010) (floxuridine)
6,520	730	5,251	3,556	323	280

Protein Interaction Comparison

Protein	Taxonomy	sorafenib (IC50)	floxuridine (IC50)
Thymidylate synthase	Mus musculus (house mouse)		1.0862

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Chang, J; Jiang, J; Kang, J; Li, E; Li, L; Liu, B; Peng, Y; Wang, Q; Wang, Y; Wu, J; Yang, Q; Yu, W; Zhang, J	1
Escudier, B; Gore, ME	1
Bi, F; Tang, Q; Xu, H; Zhang, H	1

Reviews

1 review(s) available for sorafenib and floxuridine

Article	Year
Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma. Oncology (Williston Park, N.Y.), 2006, Volume: 20, Issue:6 Suppl 5 Topics: Antimetabolites, Antineoplastic; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Drug Delivery Systems; Endpoint Determination; Floxuridine; Fluorouracil; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Risk; Sorafenib; Survival Analysis; Treatment Outcome	2006

Article

Year

Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma.

Oncology (Williston Park, N.Y.), 2006, Volume: 20, Issue:6 Suppl 5

Topics: Antimetabolites, Antineoplastic; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Drug Delivery Systems; Endpoint Determination; Floxuridine; Fluorouracil; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Risk; Sorafenib; Survival Analysis; Treatment Outcome

2006

Other Studies

2 other study(ies) available for sorafenib and floxuridine

Article	Year
Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma. Journal of medicinal chemistry, 2016, 04-28, Volume: 59, Issue:8 Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Carcinoma, Hepatocellular; Deoxyuridine; Drug Discovery; Liver; Liver Neoplasms, Experimental; Mice; Prodrugs; Rats; Rats, Sprague-Dawley; Tissue Distribution	2016
The selective serotonin reuptake inhibitors enhance the cytotoxicity of sorafenib in hepatocellular carcinoma cells. Anti-cancer drugs, 2021, 09-01, Volume: 32, Issue:8 Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Combinations; Floxuridine; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Proto-Oncogene Proteins c-akt; Selective Serotonin Reuptake Inhibitors; Sertraline; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2021

Article

Year

Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.

Journal of medicinal chemistry, 2016, 04-28, Volume: 59, Issue:8

Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Carcinoma, Hepatocellular; Deoxyuridine; Drug Discovery; Liver; Liver Neoplasms, Experimental; Mice; Prodrugs; Rats; Rats, Sprague-Dawley; Tissue Distribution

2016

The selective serotonin reuptake inhibitors enhance the cytotoxicity of sorafenib in hepatocellular carcinoma cells.

Anti-cancer drugs, 2021, 09-01, Volume: 32, Issue:8

Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Combinations; Floxuridine; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Proto-Oncogene Proteins c-akt; Selective Serotonin Reuptake Inhibitors; Sertraline; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2021